Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806000 | 0.88 | UHRF1 (0.41) | OPRM1KMT2ACCR1CCR5CCR8 | |
| SCHEMBL6888915 | 0.85 | ADRA1A (0.41) | OPRM1CCR1CCR5CCR8KDM4E | |
| SCHEMBL13805993 | 0.84 | UHRF1 (0.38) | OPRM1KMT2ACCR1CCR5CCR8 | |
| SCHEMBL15177090 | 0.82 | KMT2A (0.60) | OPRM1KMT2ACCR1CCR5CCR8 | |
| SCHEMBL16546672 | 0.81 | ADRA1A (0.39) | OPRM1CCR1CCR5CCR8ADRA1A | |
| SCHEMBL2220946 | 0.81 | SYK (0.38) | OPRM1KMT2ACCR1CCR5CCR8 | |
| SCHEMBL23778296 | 0.79 | PDE4A (0.38) | OPRM1KMT2ACCR1CCR5CCR8 | |
| SCHEMBL3323620 | 0.79 | OPRM1 (0.50) | OPRM1KMT2AADRA1A | |
| SCHEMBL23798000 | 0.79 | PIK3CA (0.37) | CCR1CCR5CCR8PIK3CA | |
| SCHEMBL3048650 | 0.77 | JAK2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2515656-B1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011149801-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | OPRM1 5/4885KMT2A 1189/4885CCR1 3765/4885 |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, OPRL1 | OPRM1 13/4885KMT2A 1470/4885CCR1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.